Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Professor Kumlesh Dev

Professor (Physiology)
BIOMEDICAL SCIENCES INSTITUTE

Professor (Trinity Inst. of Neurosciences (TCIN))


  DEMYELINATION   Drug development   Glial biology   Neuroscience
Details Date
External Examiner, MSc Clinical Neuroscience, NUI Galway, Ireland 2020-Current
Visiting Professor, Dept. Food & Drug Sciences, University of Parma, Italy 2020-Current
Fellow, Trinity College Dublin (FTCD) 2014-Current
President, Frontiers in Neurology Ireland (FIN) 2011-2017
Council Member, Society for Neuroscience Ireland 2013-2015
Council Member, Swiss Tissue Culture Society 2005-2006
Member, Society for Neuroscience 2000-Current
Editorial Board Member, Int J. Mol. Sci (Molecular Neurobiology) (invited) 2020-Current
Editorial Board Member, Brain, Behavior, and Immunity 2016-Current
Editorial Board Member, Scientific Reports 2014-Current
Editorial Board Member, Canadian Journal of Pure and Applied Sciences 2012-2014
Editorial Board Member, Journal of Biological Chemistry 2005-2011
Details Date From Date To
External Examiner, MSc Clinical Neuroscience, NUI Galway, Ireland 2020 Current
Visiting Professor, Dept. Food & Drug Sciences, University of Parma, Italy 2020 Current
Fellow, Trinity College Dublin (FTCD) 2014 Current
President, Frontiers in Neurology Ireland (FIN) 2011 2017
Council Member, Society for Neuroscience Ireland 2013 2015
Council Member, Swiss Tissue Culture Society 2005 2006
Member, Society for Neuroscience 2000 Current
Editorial Board Member, Int J. Mol. Sci (Molecular Neurobiology) (invited) 2020 Current
Editorial Board Member, Brain, Behavior, and Immunity 2016 Current
Editorial Board Member, Scientific Reports 2014 Current
Editorial Board Member, Canadian Journal of Pure and Applied Sciences 2012 2014
Editorial Board Member, Journal of Biological Chemistry 2005 2011
Velasco-Estevez M, Rolle SO, Mampay M, Dev KK, Sheridan GK., Piezo1 regulates calcium oscillations and cytokine release from astrocytes., Glia, 68, 2020, p145 - 160, Journal Article, PUBLISHED  DOI
Velasco-Estevez M, Gadalla KKE, Liñan-Barba N, Cobb S, Dev KK, Sheridan GK., Inhibition of Piezo1 attenuates demyelination in the central nervous system., Glia, 68, 2020, p356 - 375, Journal Article, PUBLISHED  DOI
Béchet S, O'Sullivan SA, Yssel J, Fagan SG, Dev KK., Fingolimod Rescues Demyelination in a Mouse Model of Krabbe's Disease., Journal of Neuroscience, 40, 2020, p3104 - 3118, Journal Article, PUBLISHED  DOI
Neyman S, Braunewell K-H, O'Connell KE, Dev KK, Manahan-Vaughan D, Inhibition of the Interaction Between Group I Metabotropic Glutamate Receptors and PDZ-Domain Proteins Prevents Hippocampal Long-Term Depression, but Not Long-Term Potentiation, Frontiers in Synaptic Neuroscience, 11, 2019, p13 , Journal Article, PUBLISHED  TARA - Full Text  DOI
Velasco-Estevez M, Mampay M, Boutin H, Chaney A, Warn P, Sharp A, Burgess E, Moeendarbary E, Dev KK, Sheridan GK., Infection Augments Expression of Mechanosensing Piezo1 Channels in Amyloid Plaque-Reactive Astrocytes., Front Aging Neurosci, 2018, p332-, Journal Article, PUBLISHED  TARA - Full Text
Rutkowska, A. and Shimshek, D.R. and Sailer, A.W. and Dev, K.K., EBI2 regulates pro-inflammatory signalling and cytokine release in astrocytes, Neuropharmacology, 133, 2018, p121-128 , Notes: [cited By 0], Journal Article, PUBLISHED  TARA - Full Text  DOI
O'Sullivan, S.A. and O'Sullivan, C. and Healy, L.M. and Dev, K.K. and Sheridan, G.K., Sphingosine 1-phosphate receptors regulate TLR4-induced CXCL5 release from astrocytes and microglia, Journal of Neurochemistry, 2018, Notes: [cited By 0; Article in Press], Journal Article, PUBLISHED  TARA - Full Text  DOI
Dutta, P. and Dargahi, L. and O'Connell, K.E. and Bolia, A. and Ozkan, B. and Sailer, A.W. and Dev, K.K., A novel modelling mechanism of PAEL receptor and GABARAPL2 interaction involved in Parkinson's disease, Neuroscience Letters, 673, 2018, p12-18 , Journal Article, PUBLISHED  DOI
O'Sullivan S, Dev K.K, Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases, Neuropharmacology, 113, 2017, p597 - 607, Journal Article, PUBLISHED  DOI  URL
O'Sullivan S.A, Velasco-Estevez M, Dev K.K, Demyelination induced by oxidative stress is regulated by sphingosine 1-phosphate receptors, GLIA, 2017, p23148-, Journal Article, PUBLISHED  DOI  URL
  

Page 1 of 11
Dev KK, 6th Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci., 186, 2017, p281 - 298, Journal Article, PUBLISHED
Dev KK, 5th Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci., 185, 2016, p169 - 185, Journal Article, PUBLISHED
Dev KK, 4th Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci., 184, 2015, p1 - 18, Journal Article, PUBLISHED
Dev KK, Neurology, Professor Kumlesh Dev sets out Ireland's position on brain disease. Irish Independent (Supplement), 2015, -, Miscellaneous, PUBLISHED
Dev KK, 3rd Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci. , 183, 2014, p71 - 85, Journal Article, PUBLISHED
Dev KK, 2nd Annual Meeting. Block MS Ireland. Neuroprotection: At the cellular, in vivo and clinical level., Irish J Med. Sci., 182, 2013, p1 - 13, Journal Article, PUBLISHED

  

Award Date
Fellow Trinity College Dublin (FTCD) 2014
My research interests lie within the area of neurosciences and drug development. This research investigates the biology of brain cells, to understand their abnormal function in disease with a view to developing new targeted therapies for brain disorders. In particular, my research focusses on brain glial cells, called astrocytes and oligodendrocytes. The purpose of these studies is to gain knowledge in glial cell biology, identify new molecular drug targets, and develop novel therapies to treat brain diseases. The research studies cellular mechanisms of disease by combining fields of molecular biology, cell science, biochemistry, pharmacology and medicine. We work integrates and collaborates within the areas of biology, medicine, engineering, pharmaceutical industry, entrepreneurship, and commercialisation to ultimately deliver medicines to market. My expertise in drug development is significant and I have a wide range of collaborative networks globally within academia and industry. I have provided leadership to large research projects within pharmaceutical industry, that have led to the successful development of follow-on compounds of the marketed drug Gilenya, the first oral therapy for multiple sclerosis. My research group was the first to demonstrate that Gilenya directly regulates brain cells. This work has been unique and substantive, it has transformed our understanding in the field, and most importantly has been fundamental to the development new strategies for making follow-on drugs. I currently lead the Drug Development group at Trinity, which investigates mechanisms underlying demyelinating disorders, as well as neuro-inflammatory and neurodegenerative diseases. We have primarily focussed on diseases such as multiple sclerosis, Alzheimer's Disease, Parkinson's Disease and Niemann Pick Disease Type C, and more recently investigating the rare paediatric demyelinating disorder, Krabbes disease. The research activities of my group draw upon close collaborations in the academic, medical and industrial arenas, both nationally and internationally. This research has provided a method for continued research funding and dissemination success, excellence and impact. The research is well supported by highly competitive national and international funding agencies as well as multinational pharmaceutical industry. The research has been funded in kind and in part by Trinity College Dublin, Science Foundation Ireland, Health Research Board Ireland, Enterprise Ireland, The Wellcome Trust and industry including Lundbeck, Actelion, Servier and Novartis. With several years of experience in the area of demyelinating diseases, I have published extensively on glial cell biology and processes of myelination. My research group has shown that development compounds and marketed drugs can rescue toxin-induced glia cell death, reactivity and demyelination as well as damage of neurons. My research has demonstrated methods that can increase the lifespan of twitcher mice, an animal mouse model of Krabbes disease. All of these findings have been published in high quality journals and are the subject of international recognition. My research has been continued and sustained, moving from cellular experiments to animal disease model studies and paving the way for clinical development. Altogether, these activities are transformational in nature and based on a global reputation in the area of glial cell biology and drug development. Having developed research and infrastructure that integrates in vitro, ex vivo and in vivo approaches to study mechanisms of brain diseases, my vision for the future, over the next 5 years, is to build a research programme that integrates neuroscience and drug development within Trinity. The aim is to provide a research platform that allows for the generation of novel intellectual property, which can be exploited for out-licencing activities and/or be developed toward market.